Details of the Drug

General Information of Drug (ID: DMXLKHV)

Drug Name
Oxycodone
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1], [2]
Back pain ME84.Z Phase 3 [3]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 315.4
Topological Polar Surface Area (xlogp) 1.2
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The total plasma clearance of drug is 1.4 L/min [5]
Elimination
19% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.2 hours [6]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.05589 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.55% [8]
Vd
The volume of distribution (Vd) of drug is 2.6 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 100 mg/mL [4]
Chemical Identifiers
Formula
C18H21NO4
IUPAC Name
(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Canonical SMILES
CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O
InChI
InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
InChIKey
BRUQQQPBMZOVGD-XFKAJCMBSA-N
Cross-matching ID
PubChem CID
5284603
ChEBI ID
CHEBI:7852
CAS Number
76-42-6
DrugBank ID
DB00497
TTD ID
D03SKD
VARIDT ID
DR00392
ACDINA ID
D00502

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor delta (OPRD1) TT27RFC OPRD_HUMAN Agonist [9]
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Modulator [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pain
ICD Disease Classification MG30-MG3Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor mu (MOP) DTT OPRM1 5.94E-01 -0.02 -0.17
Opioid receptor delta (OPRD1) DTT OPRD1 5.52E-01 0.03 0.23
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Oxycodone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pentazocine DM1XBHS Major Additive hypotensive effects by the combination of Oxycodone and Pentazocine. Pain [MG30-MG3Z] [28]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Oxycodone and Dextropropoxyphene. Pain [MG30-MG3Z] [29]
Butorphanol DM5KYPJ Major Additive hypotensive effects by the combination of Oxycodone and Butorphanol. Pain [MG30-MG3Z] [28]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Oxycodone and Oxymorphone. Pain [MG30-MG3Z] [30]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Oxycodone and Levorphanol. Pain [MG30-MG3Z] [30]
Dezocine DMJDB0Y Major Additive hypotensive effects by the combination of Oxycodone and Dezocine. Pain [MG30-MG3Z] [28]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Oxycodone and Flavoxate. Pain [MG30-MG3Z] [31]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Oxycodone and Nalbuphine. Pain [MG30-MG3Z] [28]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Oxycodone and Buprenorphine. Pain [MG30-MG3Z] [28]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Oxycodone and Hydrocodone. Pain [MG30-MG3Z] [30]
⏷ Show the Full List of 10 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Oxycodone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Oxycodone caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [32]
Ivosidenib DM8S6T7 Major Increased metabolism of Oxycodone caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [33]
Arn-509 DMT81LZ Major Increased metabolism of Oxycodone caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [33]
Emapalumab DMZG5WL Moderate Altered metabolism of Oxycodone due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [34]
Scopolamine DMOM8AL Moderate Additive CNS depression effects by the combination of Oxycodone and Scopolamine. Addictive disorder [6C50-6C5Z] [31]
Mitotane DMU1GX0 Major Increased metabolism of Oxycodone caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [33]
Siltuximab DMGEATB Moderate Altered metabolism of Oxycodone due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [34]
Dronedarone DMA8FS5 Major Decreased metabolism of Oxycodone caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [35]
Clorazepate DMC3JST Major Additive CNS depression effects by the combination of Oxycodone and Clorazepate. Anxiety disorder [6B00-6B0Z] [36]
Methylphenobarbital DMDSWAG Major Increased metabolism of Oxycodone caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [37]
Hydroxyzine DMF8Y74 Major Additive CNS depression effects by the combination of Oxycodone and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [30]
Halazepam DMPFWO6 Major Additive CNS depression effects by the combination of Oxycodone and Halazepam. Anxiety disorder [6B00-6B0Z] [30]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Oxycodone and Chlormezanone. Anxiety disorder [6B00-6B0Z] [30]
Oxazepam DMXNZM4 Major Additive CNS depression effects by the combination of Oxycodone and Oxazepam. Anxiety disorder [6B00-6B0Z] [30]
Voriconazole DMAOL2S Major Decreased metabolism of Oxycodone caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [35]
Posaconazole DMUL5EW Major Decreased metabolism of Oxycodone caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [35]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Oxycodone caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [35]
Desipramine DMT2FDC Moderate Additive serotonergic effects by the combination of Oxycodone and Desipramine. Attention deficit hyperactivity disorder [6A05] [38]
Oritavancin DM28D05 Moderate Increased metabolism of Oxycodone caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [32]
Ciprofloxacin XR DM2NLS9 Major Decreased metabolism of Oxycodone caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Dalfopristin DM4LTKV Major Decreased metabolism of Oxycodone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Clarithromycin DM4M1SG Major Decreased metabolism of Oxycodone caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Troleandomycin DMUZNIG Major Decreased metabolism of Oxycodone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Telithromycin DMZ4P3A Major Decreased metabolism of Oxycodone caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Oxycodone and Cariprazine. Bipolar disorder [6A60] [30]
Erdafitinib DMI782S Moderate Increased metabolism of Oxycodone caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [39]
Loperamide DMOJZQ9 Moderate Additive CNS depression effects by the combination of Oxycodone and Loperamide. Bowel habit change [ME05] [34]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Oxycodone caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Tucatinib DMBESUA Major Decreased metabolism of Oxycodone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Palbociclib DMD7L94 Moderate Decreased metabolism of Oxycodone caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Oxycodone caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [32]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Oxycodone and Dihydrocodeine. Chronic pain [MG30] [36]
Levomilnacipran DMV26S8 Moderate Additive serotonergic effects by the combination of Oxycodone and Levomilnacipran. Chronic pain [MG30] [38]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Oxycodone and Olopatadine. Conjunctiva disorder [9A60] [40]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Oxycodone and Propofol. Corneal disease [9A76-9A78] [41]
Dextromethorphan DMUDJZM Moderate Additive serotonergic effects by the combination of Oxycodone and Dextromethorphan. Cough [MD12] [38]
Mifepristone DMGZQEF Major Decreased metabolism of Oxycodone caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [35]
Pasireotide DMHM7JS Moderate Decreased metabolism of Oxycodone caused by Pasireotide mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [35]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Oxycodone caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [35]
Lumacaftor DMCLWDJ Major Increased metabolism of Oxycodone caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [42]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Oxycodone caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [35]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Oxycodone and Ethanol. Cystitis [GC00] [43]
MK-8228 DMOB58Q Major Decreased metabolism of Oxycodone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [35]
Aprepitant DM053KT Major Decreased metabolism of Oxycodone caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Sertraline DM0FB1J Moderate Additive serotonergic effects by the combination of Oxycodone and Sertraline. Depression [6A70-6A7Z] [38]
Trimipramine DM1SC8M Moderate Additive serotonergic effects by the combination of Oxycodone and Trimipramine. Depression [6A70-6A7Z] [38]
Cyclobenzaprine DM1YBRM Major Additive CNS depression effects by the combination of Oxycodone and Cyclobenzaprine. Depression [6A70-6A7Z] [30]
Nortriptyline DM4KDYJ Moderate Additive serotonergic effects by the combination of Oxycodone and Nortriptyline. Depression [6A70-6A7Z] [38]
Nefazodone DM4ZS8M Major Decreased metabolism of Oxycodone caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Paroxetine DM5PVQE Moderate Additive serotonergic effects by the combination of Oxycodone and Paroxetine. Depression [6A70-6A7Z] [38]
Vortioxetine DM6F1PU Moderate Additive serotonergic effects by the combination of Oxycodone and Vortioxetine. Depression [6A70-6A7Z] [38]
Milnacipran DMBFE74 Moderate Additive serotonergic effects by the combination of Oxycodone and Milnacipran. Depression [6A70-6A7Z] [38]
Escitalopram DMFK9HG Moderate Additive serotonergic effects by the combination of Oxycodone and Escitalopram. Depression [6A70-6A7Z] [38]
Desvenlafaxine DMHD4PE Moderate Additive serotonergic effects by the combination of Oxycodone and Desvenlafaxine. Depression [6A70-6A7Z] [38]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Oxycodone and OPC-34712. Depression [6A70-6A7Z] [30]
Clomipramine DMINRKW Moderate Additive serotonergic effects by the combination of Oxycodone and Clomipramine. Depression [6A70-6A7Z] [38]
Trazodone DMK1GBJ Moderate Additive serotonergic effects by the combination of Oxycodone and Trazodone. Depression [6A70-6A7Z] [38]
Amoxapine DMKITQE Moderate Additive serotonergic effects by the combination of Oxycodone and Amoxapine. Depression [6A70-6A7Z] [38]
Doxepin DMPI98T Moderate Additive serotonergic effects by the combination of Oxycodone and Doxepin. Depression [6A70-6A7Z] [38]
Maprotiline DMPWB7T Moderate Additive serotonergic effects by the combination of Oxycodone and Maprotiline. Depression [6A70-6A7Z] [38]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Oxycodone and Esketamine. Depression [6A70-6A7Z] [35]
Mepenzolate DM8YU2F Moderate Additive CNS depression effects by the combination of Oxycodone and Mepenzolate. Digestive system disease [DE2Z] [31]
5-hydroxy-L-tryptophan DMDWZGJ Moderate Additive serotonergic effects by the combination of Oxycodone and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [38]
Oxybutynine DMJPBAX Moderate Additive CNS depression effects by the combination of Oxycodone and Oxybutynine. Discovery agent [N.A.] [31]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Oxycodone and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [36]
Fenfluramine DM0762O Moderate Additive serotonergic effects by the combination of Oxycodone and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [38]
Primidone DM0WX6I Major Additive CNS depression effects by the combination of Oxycodone and Primidone. Epilepsy/seizure [8A61-8A6Z] [31]
Felbamate DM1V5ZS Moderate Increased metabolism of Oxycodone caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Oxcarbazepine DM5PU6O Major Increased metabolism of Oxycodone caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Oxycodone and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [44]
Cenobamate DMGOVHA Major Increased metabolism of Oxycodone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [33]
Stiripentol DMMSDOY Major Decreased metabolism of Oxycodone caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Fosphenytoin DMOX3LB Major Increased metabolism of Oxycodone caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Oxycodone and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [30]
Rufinamide DMWE60C Moderate Increased metabolism of Oxycodone caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Phenobarbital DMXZOCG Major Increased metabolism of Oxycodone caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Carbamazepine DMZOLBI Major Increased metabolism of Oxycodone caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Eslicarbazepine DMZREFQ Major Increased metabolism of Oxycodone caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Oxycodone and Dantrolene. Fever [MG26] [30]
Tazemetostat DMWP1BH Moderate Increased metabolism of Oxycodone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [32]
Solifenacin DMG592Q Moderate Additive CNS depression effects by the combination of Oxycodone and Solifenacin. Functional bladder disorder [GC50] [31]
Tolterodine DMSHPW8 Moderate Additive CNS depression effects by the combination of Oxycodone and Tolterodine. Functional bladder disorder [GC50] [31]
Itraconazole DMCR1MV Major Decreased metabolism of Oxycodone caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [35]
Terbinafine DMI6HUW Moderate Decreased metabolism of Oxycodone caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [45]
Ketoconazole DMPZI3Q Major Decreased metabolism of Oxycodone caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [35]
Propantheline DM2EN6G Moderate Additive CNS depression effects by the combination of Oxycodone and Propantheline. Gastric ulcer [DA60] [31]
Cimetidine DMH61ZB Major Decreased metabolism of Oxycodone caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [35]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Oxycodone caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [32]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Oxycodone and Bumetanide. Heart failure [BD10-BD1Z] [46]
Boceprevir DMBSHMF Major Decreased metabolism of Oxycodone caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Simeprevir DMLUA9D Moderate Decreased metabolism of Oxycodone caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Telaprevir DMMRV29 Major Decreased metabolism of Oxycodone caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Oxycodone caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [35]
Rifampin DMA8J1G Major Increased metabolism of Oxycodone caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [42]
Rifapentine DMCHV4I Major Increased metabolism of Oxycodone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [33]
Delavirdine DM3NF5G Major Decreased metabolism of Oxycodone caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Oxycodone caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Cobicistat DM6L4H2 Major Decreased metabolism of Oxycodone caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Efavirenz DMC0GSJ Major Increased metabolism of Oxycodone caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [33]
Etravirine DMGV8QU Major Increased metabolism of Oxycodone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [33]
Amprenavir DMLMXE0 Major Decreased metabolism of Oxycodone caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Darunavir DMN3GCH Major Decreased metabolism of Oxycodone caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Atazanavir DMSYRBX Major Decreased metabolism of Oxycodone caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Ritonavir DMU764S Major Decreased metabolism of Oxycodone caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [47]
Verapamil DMA7PEW Major Decreased metabolism of Oxycodone caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [35]
Conivaptan DM1V329 Major Decreased metabolism of Oxycodone caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [35]
Belladonna DM2RBWK Moderate Additive antimotility effects by the combination of Oxycodone and Belladonna. Infectious gastroenteritis/colitis [1A40] [31]
Berotralstat DMWA2DZ Major Decreased metabolism of Oxycodone caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [35]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Oxycodone and Suvorexant. Insomnia [7A00-7A0Z] [30]
Amobarbital DM0GQ8N Major Increased metabolism of Oxycodone caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Oxycodone and Ramelteon. Insomnia [7A00-7A0Z] [30]
Flurazepam DMAL4G0 Major Additive CNS depression effects by the combination of Oxycodone and Flurazepam. Insomnia [7A00-7A0Z] [30]
Triazolam DMETYK5 Major Additive CNS depression effects by the combination of Oxycodone and Triazolam. Insomnia [7A00-7A0Z] [30]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Oxycodone and Zaleplon. Insomnia [7A00-7A0Z] [30]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Oxycodone and Propiomazine. Insomnia [7A00-7A0Z] [30]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Oxycodone and Tasimelteon. Insomnia [7A00-7A0Z] [30]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Oxycodone and Paraldehyde. Insomnia [7A00-7A0Z] [30]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Oxycodone and ITI-007. Insomnia [7A00-7A0Z] [30]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Oxycodone and Quazepam. Insomnia [7A00-7A0Z] [30]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Oxycodone and Estazolam. Insomnia [7A00-7A0Z] [30]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Oxycodone and Polyethylene glycol. Irritable bowel syndrome [DD91] [48]
Clidinium DMUMQZ0 Moderate Additive antimotility effects by the combination of Oxycodone and Clidinium. Irritable bowel syndrome [DD91] [31]
Dicyclomine DMZSDGX Moderate Additive antimotility effects by the combination of Oxycodone and Dicyclomine. Irritable bowel syndrome [DD91] [31]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Oxycodone and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [30]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Oxycodone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [34]
Crizotinib DM4F29C Major Decreased metabolism of Oxycodone caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [35]
Ceritinib DMB920Z Major Decreased metabolism of Oxycodone caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [35]
PF-06463922 DMKM7EW Major Increased metabolism of Oxycodone caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [33]
Osimertinib DMRJLAT Moderate Increased metabolism of Oxycodone caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [34]
Selpercatinib DMZR15V Moderate Decreased metabolism of Oxycodone caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [35]
Lumefantrine DM29GAD Moderate Decreased metabolism of Oxycodone caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [35]
Idelalisib DM602WT Major Decreased metabolism of Oxycodone caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [35]
IPI-145 DMWA24P Major Decreased metabolism of Oxycodone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [35]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Oxycodone caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [49]
Vemurafenib DM62UG5 Moderate Increased metabolism of Oxycodone caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [32]
LGX818 DMNQXV8 Moderate Increased metabolism of Oxycodone caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [50]
Dabrafenib DMX6OE3 Major Increased metabolism of Oxycodone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [33]
Danazol DML8KTN Moderate Decreased metabolism of Oxycodone caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [35]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Oxycodone and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [51]
Almogran DM7I64Z Moderate Additive serotonergic effects by the combination of Oxycodone and Almogran. Migraine [8A80] [38]
Frovatriptan DM7RE8P Moderate Additive serotonergic effects by the combination of Oxycodone and Frovatriptan. Migraine [8A80] [38]
Rizatriptan DMDJMA3 Moderate Additive serotonergic effects by the combination of Oxycodone and Rizatriptan. Migraine [8A80] [38]
Naratriptan DMO50U2 Moderate Additive serotonergic effects by the combination of Oxycodone and Naratriptan. Migraine [8A80] [38]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Oxycodone and Lasmiditan. Migraine [8A80] [52]
Exjade DMHPRWG Moderate Increased metabolism of Oxycodone caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [32]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Oxycodone and Flibanserin. Mood disorder [6A60-6E23] [53]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Oxycodone and Thalidomide. Multiple myeloma [2A83] [54]
Rifabutin DM1YBHK Major Increased metabolism of Oxycodone caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [33]
Fedratinib DM4ZBK6 Major Decreased metabolism of Oxycodone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [35]
Nilotinib DM7HXWT Moderate Decreased metabolism of Oxycodone caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [35]
Imatinib DM7RJXL Major Decreased metabolism of Oxycodone caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [35]
Prasugrel DM7MT6E Moderate Altered absorption of Oxycodone due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [55]
Modafinil DMYILBE Major Increased metabolism of Oxycodone caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [33]
Netupitant DMEKAYI Major Decreased metabolism of Oxycodone caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [35]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Oxycodone when combined with Metoclopramide. Nausea/vomiting [MD90] [56]
Granisetron DMIUW25 Moderate Additive serotonergic effects by the combination of Oxycodone and Granisetron. Nausea/vomiting [MD90] [38]
Dolasetron DMMG26Z Moderate Additive serotonergic effects by the combination of Oxycodone and Dolasetron. Nausea/vomiting [MD90] [38]
Ondansetron DMOTQ1I Moderate Additive serotonergic effects by the combination of Oxycodone and Ondansetron. Nausea/vomiting [MD90] [38]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Oxycodone and Bupropion. Nicotine use disorder [6C4A] [57]
Sibutramine DMFJTDI Moderate Additive serotonergic effects by the combination of Oxycodone and Sibutramine. Obesity [5B80-5B81] [38]
Dexfenfluramine DMJ7YDS Moderate Additive serotonergic effects by the combination of Oxycodone and Dexfenfluramine. Obesity [5B80-5B81] [38]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Oxycodone and Levomethadyl Acetate. Opioid use disorder [6C43] [36]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Oxycodone and Apraclonidine. Optic nerve disorder [9C40] [58]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Oxycodone caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [35]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Oxycodone and Biperiden. Parkinsonism [8A00] [59]
Pimavanserin DMR7IVC Major Additive CNS depression effects by the combination of Oxycodone and Pimavanserin. Parkinsonism [8A00] [30]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Oxycodone and Orphenadrine. Parkinsonism [8A00] [30]
Abametapir DM2RX0I Moderate Decreased metabolism of Oxycodone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [60]
Methylscopolamine DM5VWOB Moderate Additive CNS depression effects by the combination of Oxycodone and Methylscopolamine. Peptic ulcer [DA61] [31]
Lanreotide acetate DMG6ZU4 Moderate Decreased metabolism of Oxycodone caused by Lanreotide acetate mediated inhibition of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [35]
Lefamulin DME6G97 Moderate Decreased metabolism of Oxycodone caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [61]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Oxycodone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [35]
ABIRATERONE DM8V75C Major Decreased metabolism of Oxycodone caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [35]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Oxycodone due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [34]
Ixekizumab DMXW92T Moderate Altered metabolism of Oxycodone due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [34]
Triflupromazine DMKFQJP Major Additive CNS depression effects by the combination of Oxycodone and Triflupromazine. Psychotic disorder [6A20-6A25] [30]
Bosentan DMIOGBU Major Increased metabolism of Oxycodone caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [33]
Tocilizumab DM7J6OR Moderate Altered metabolism of Oxycodone due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [34]
Canakinumab DM8HLO5 Moderate Altered metabolism of Oxycodone due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [34]
Rilonacept DMGLUQS Moderate Altered metabolism of Oxycodone due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [34]
Golimumab DMHZV7X Moderate Altered metabolism of Oxycodone due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [34]
Nafcillin DMN9RPO Major Increased metabolism of Oxycodone caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [33]
Sarilumab DMOGNXY Moderate Altered metabolism of Oxycodone due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [34]
Mesoridazine DM2ZGAN Major Additive CNS depression effects by the combination of Oxycodone and Mesoridazine. Schizophrenia [6A20] [62]
Thioridazine DM35M8J Major Additive CNS depression effects by the combination of Oxycodone and Thioridazine. Schizophrenia [6A20] [30]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Oxycodone and Aripiprazole. Schizophrenia [6A20] [30]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Oxycodone and Iloperidone. Schizophrenia [6A20] [30]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Oxycodone and Paliperidone. Schizophrenia [6A20] [30]
Haloperidol DM96SE0 Major Additive CNS depression effects by the combination of Oxycodone and Haloperidol. Schizophrenia [6A20] [30]
Perphenazine DMA4MRX Major Additive CNS depression effects by the combination of Oxycodone and Perphenazine. Schizophrenia [6A20] [30]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Oxycodone and Molindone. Schizophrenia [6A20] [30]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Oxycodone and Thiothixene. Schizophrenia [6A20] [62]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Oxycodone and Trifluoperazine. Schizophrenia [6A20] [30]
Risperidone DMN6DXL Major Additive CNS depression effects by the combination of Oxycodone and Risperidone. Schizophrenia [6A20] [30]
Asenapine DMSQZE2 Major Additive CNS depression effects by the combination of Oxycodone and Asenapine. Schizophrenia [6A20] [30]
Pimozide DMW83TP Major Additive CNS depression effects by the combination of Oxycodone and Pimozide. Schizophrenia [6A20] [30]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Oxycodone and Fentanyl. Sensation disturbance [MB40] [30]
Voxelotor DMCS6M5 Major Decreased metabolism of Oxycodone caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [35]
Telotristat ethyl DMDIYFZ Major Increased metabolism of Oxycodone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [42]
Larotrectinib DM26CQR Moderate Decreased metabolism of Oxycodone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Armodafinil DMGB035 Major Increased metabolism of Oxycodone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [33]
LEE011 DMMX75K Major Decreased metabolism of Oxycodone caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Oxycodone caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [63]
Brilinta DMBR01X Moderate Altered absorption of Oxycodone due to GI dynamics variation caused by Brilinta. Thrombosis [DB61-GB90] [55]
Clopidogrel DMOL54H Moderate Altered absorption of Oxycodone due to GI dynamics variation caused by Clopidogrel. Thrombosis [DB61-GB90] [55]
Tizanidine DMR2IQ4 Major Additive CNS depression effects by the combination of Oxycodone and Tizanidine. Tonus and reflex abnormality [MB47] [30]
Elagolix DMB2C0E Major Increased metabolism of Oxycodone caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [33]
⏷ Show the Full List of 207 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
D&C red no. 27 E00381 83511 Colorant
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Myristic acid E00204 11005 Emulsifying agent; Penetration agent; lubricant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Aluminum trihydroxide E00505 10176082 Alkalizing agent; Vaccine adjuvant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Dibutyl sebacate E00160 7986 Plasticizing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate E00671 Not Available Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Sorbic acid E00441 643460 Antimicrobial preservative
Stearyl alcohol E00172 8221 Emollient; Emulsifying agent; Stiffening agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
⏷ Show the Full List of 38 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Oxycodone 15 mg tablet 15 mg Abuse-Deterrent Oral Tablet Oral
Oxycodone 30 mg tablet 30 mg Abuse-Deterrent Oral Tablet Oral
Oxycodone 5 mg tablet 5 mg Abuse-Deterrent Oral Tablet Oral
Oxycodone 80 mg tablet 80 mg 12 HR Extended Release Oral Tablet Oral
Oxycodone 60 mg tablet 60 mg 12 HR Extended Release Oral Tablet Oral
Oxycodone 80 mg tablet 80 mg Abuse-Deterrent 12 HR Extended Release Oral Tablet Oral
Oxycodone 5 mg capsule 5 mg Oral Capsule Oral
Oxycodone 30 mg tablet 30 mg 12 HR Extended Release Tablet Oral
Oxycodone 30 mg tablet 30 mg Abuse-Deterrent 12 HR Extended Release Oral Tablet Oral
Oxycodone 60 mg tablet 60 mg Abuse-Deterrent 12 HR Extended Release Oral Tablet Oral
Oxycodone 60 mg tablet 60 mg 12 HR Extended Release Tablet Oral
Oxycodone 20 mg tablet 20 mg Abuse-Deterrent 12 HR Extended Release Oral Tablet Oral
Oxycodone 20 mg tablet 20 mg 12 HR Extended Release Tablet Oral
Oxycodone 40 mg tablet 40 mg 12 HR Extended Release Tablet Oral
Oxycodone 80 mg tablet 80 mg 12 HR Extended Release Tablet Oral
Oxycodone 15 mg tablet 15 mg Abuse-Deterrent 12 HR Extended Release Oral Tablet Oral
Oxycodone 13.5 mg capsule 13.5 mg Abuse-Deterrent 12 HR Extended Release Oral Capsule Oral
Oxycodone 18 mg capsule 18 mg Abuse-Deterrent 12 HR Extended Release Oral Capsule Oral
Oxycodone 27 mg capsule 27 mg Abuse-Deterrent 12 HR Extended Release Oral Capsule Oral
Oxycodone 36 mg capsule 36 mg Abuse-Deterrent 12 HR Extended Release Oral Capsule Oral
Oxycodone 9 mg capsule 9 mg Abuse-Deterrent 12 HR Extended Release Oral Capsule Oral
Oxycodone 15 mg tablet 15 mg Oral Tablet Oral
Oxycodone 20 mg tablet 20 mg Oral Tablet Oral
Oxycodone 10 mg tablet 10 mg Abuse-Deterrent 12 HR Extended Release Oral Tablet Oral
Oxycodone 10 mg tablet 10 mg 12 HR Extended Release Tablet Oral
Oxycodone 30 mg tablet 30 mg Oral Tablet Oral
Oxycodone 10 mg tablet 10 mg Oral Tablet Oral
Oxycodone 5 mg tablet 5 mg Oral Tablet Oral
Oxycodone 20 mg tablet 20 mg 12 HR Extended Release Oral Tablet Oral
Oxycodone 40 mg tablet 40 mg 12 HR Extended Release Oral Tablet Oral
Oxycodone 40 mg tablet 40 mg Abuse-Deterrent 12 HR Extended Release Oral Tablet Oral
Oxycodone 10 mg tablet 10 mg 12 HR Extended Release Oral Tablet Oral
Oxycodone 15 mg tablet 15 mg 12 HR Extended Release Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7093).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 085910.
3 ClinicalTrials.gov (NCT01427283) A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain. U.S. National Institutes of Health.
4 BDDCS applied to over 900 drugs
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Metabolism and Disposition of Prescription Opioids: A Review. Forensic Sci Rev. 2015 Jul;27(2):115-45.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
11 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
12 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
13 Clinical pipeline report, company report or official report of signaturerx.
14 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
15 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
16 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
17 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
18 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
19 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
20 Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
21 Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
22 Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
23 Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
24 Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
25 Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
26 Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
28 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
29 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
30 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
31 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
32 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
33 Canadian Pharmacists Association.
34 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
35 Cerner Multum, Inc. "Australian Product Information.".
36 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
37 Liu S-J, Wang RI "Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome." Am J Psychiatry 141 (1984): 1287-8. [PMID: 6486271]
38 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
39 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
40 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
41 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
42 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
43 Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
44 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
45 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
46 Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595. [PMID: 9518913]
47 Lalovic B, Phillips B, Risler LL, Howald W, Shen DD "Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes." Drug Metab Dispos 32 (2004): 447-54. [PMID: 15039299]
48 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
49 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
50 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
51 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
52 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
53 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
54 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
55 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
56 Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
57 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
58 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
59 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
60 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
61 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
62 Cerner Multum, Inc. "Canadian Product Information.".
63 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.